Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Skirnisdottir, Ingiridur ^a   Mayrhofer, Markus ^a   Rydåker, Maria ^a   Åkerud, Helena ^a   Isaksson, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Allele specific copy number; Early stage; FFPE; LOH; Prognosis; Serous ovarian cancer; TAPS

Indexed keywords

FORMALDEHYDE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 19Q; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; GENE DOSAGE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION; TUMOR CELL;

ALLELES; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE DOSAGE; GENOMICS; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866014702     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-407     Document Type: Article

References (40)

1. Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2010, 116:307-311. 10.1016/j.ygyno.2009.10.074, 19944452.
2. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
3. Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002, 62:4722-4729.
4. Bonome T, Lee J-Y, Park D-C, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005, 65:10602-10612. 10.1158/0008-5472.CAN-05-2240, 16288054.
5. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005, 11:3686-3696. 10.1158/1078-0432.CCR-04-2398, 15897565.
6. Lawrenson K, Gayther SA. Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 2009, 6:e25. 10.1371/journal.pmed.1000025, 2634795, 19192945.
7. Chien J, Fan J-B, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol 2009, 114:3-11. 10.1016/j.ygyno.2009.04.002, 19410283.
8. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518. 10.1016/S0002-9440(10)63708-X, 1615664, 15111296.
9. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009, 15:2448-2455. 10.1158/1078-0432.CCR-08-2430, 3050629, 19318476.
10. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynaecol Obstet 2003, 83(Suppl 1):135-166.
11. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010, 116:50-56. 10.1016/j.ygyno.2009.09.029, 19822358.
12. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003, 91:504-512. 10.1016/j.ygyno.2003.08.034, 14675668.
13. Darcy KM, Birrer MJ. Translational research in the gynecologic oncology group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 2010, 117:429-439. 10.1016/j.ygyno.2010.01.048, 2877379, 20233625.
14. Birrer MJ, Johnson ME, Hao K, Wong K-K, Park D-C, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007, 25:2281-2287. 10.1200/JCO.2006.09.0795, 17538174.
15. Kwon JY, Seo YR, Ahn WS. Recognition of potential predictive markers for diagnosis in Korean serous ovarian cancer patients at stage IIIc using array comparative genomic hybridization with high resolution. Mol Cell Toxicolo 2011, 7:77-86.
16. Rasmussen M, Sundström M, Kultima HG, Botling J, Micke P, Birgisson H, Glimelius B, Isaksson A. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol 2011, 12:R108. 10.1186/gb-2011-12-10-r108, 3333778, 22023820.
17. Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, Werner M. A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J Mol Med 2009, 87:211-224. 10.1007/s00109-008-0419-y, 19066834.
18. Skírnisdóttir I, Seidal T. The apoptosis regulators p53, bax and PUMA: relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment. Oncol Rep 2012, 27:741-747.
19. Skírnisdóttir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 2011, 21:236-244. 10.1097/IGC.0b013e31820986e5, 21270607.
20. Skírnisdóttir I, Seidal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 2011, 21:1024-1031. 10.1097/IGC.0b013e31821dc906, 21792012.
21. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003, 95:113-125. 10.1093/jnci/95.2.113, 12529344.
22. WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html..
23. Affymetrix research services laboratory. http://www.affymetrix.com/products_services/services/..
24. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23:657-663. 10.1093/bioinformatics/btl646, 17234643.
25. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001, 357(9251):176-182. 10.1016/S0140-6736(00)03590-X, 11213094.
26. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008, 5:577-587. 10.1038/ncponc1178, 18648354.
27. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DDL. Australian ovarian cancer study: copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 2010, 5:e11408. 10.1371/journal.pone.0011408, 2937017, 20844748.
28. Etemadmoghadam D, DeFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew Y-E, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Canc Res 2009, 15:1417-1427.
29. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. 10.1038/nature10166, 3163504, 21720365.
30. Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE 2011, 6:e28503. 10.1371/journal.pone.0028503, 3234280, 22174824.
31. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 2009, 48:931-942. 10.1002/gcc.20694, 19603523.
32. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DYH, Campbell IG. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007, 13:4731-4739. 10.1158/1078-0432.CCR-07-0502, 17699850.
33. Baudis M. Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001, 17:1228-1229. 10.1093/bioinformatics/17.12.1228, 11751233.
34. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol 2010, 221:49-56. 10.1002/path.2696, 3262968, 20229506.
35. Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecologic Oncology 1997, 66:36-40. 10.1006/gyno.1997.4709, 9234918.
36. The human protein atlas. http://www.proteinatlas.org/..
37. Gunnarsson R, Isaksson A, Mansouri M, Göransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2009, 24:211-215.
38. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7:673-682. 10.1016/S1097-2765(01)00213-1, 11463391.
39. Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers a gynecologic oncology group study. Gynecol Oncol 2008, 111:487-495. 10.1016/j.ygyno.2008.08.020, 2615492, 18834621.
40. Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E, Sidransky D. PUMA in head and neck cancer. Cancer Lett 2003, 199:75-81. 10.1016/S0304-3835(03)00344-6, 12963126.